GLAUPREXA - Trademark Details
Status: 606 - Abandoned - No Statement Of Use Filed
Serial Number
87379490
Word Mark
GLAUPREXA
Status
606 - Abandoned - No Statement Of Use Filed
Status Date
2021-01-04
Filing Date
2017-03-21
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2017-06-06
Law Office Assigned Location Code
L90
Employee Name
LATTUCA, FRANK J
Statements
Goods and Services
Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2017-03-24
Primary Code
005
Correspondences
Name
Allergan, Inc.
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2017-03-24 | NEW APPLICATION ENTERED IN TRAM |
2017-03-24 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2017-04-24 | ASSIGNED TO EXAMINER |
2017-04-27 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2017-05-17 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2017-06-06 | PUBLISHED FOR OPPOSITION |
2017-06-06 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2017-06-28 | EXTENSION OF TIME TO OPPOSE RECEIVED |
2017-07-07 | TEAS POST PUBLICATION AMENDMENT RECEIVED |
2017-07-12 | ASSIGNED TO PETITION STAFF |
2017-07-15 | CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED |
2017-10-15 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
2017-11-28 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2018-04-30 | TEAS EXTENSION RECEIVED |
2018-04-30 | EXTENSION 1 FILED |
2018-04-30 | EXTENSION 1 GRANTED |
2018-05-02 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2018-10-26 | TEAS EXTENSION RECEIVED |
2018-10-26 | EXTENSION 2 FILED |
2018-10-26 | EXTENSION 2 GRANTED |
2018-10-30 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2019-03-12 | TEAS EXTENSION RECEIVED |
2019-03-12 | EXTENSION 3 FILED |
2019-03-12 | EXTENSION 3 GRANTED |
2019-03-14 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2019-11-06 | TEAS EXTENSION RECEIVED |
2019-11-06 | EXTENSION 4 FILED |
2019-11-06 | EXTENSION 4 GRANTED |
2019-11-08 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2020-04-13 | TEAS EXTENSION RECEIVED |
2020-04-15 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2020-04-13 | EXTENSION 5 FILED |
2020-04-15 | EXTENSION 5 GRANTED |
2020-04-16 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2021-01-04 | ABANDONMENT - NO USE STATEMENT FILED |
2021-01-04 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |